Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Hermiller

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|April 1, 2014
Transcatheter aortic-valve replacement with a self-expanding prosthesisDavid H Adams, Jeffrey J Popma, Michael J Reardon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 18, 2021
Early outcomes from the CLASP IID trial roll-in cohort for prohibitive risk patients with degenerative mitral regurgitationD Scott Lim, Robert L Smith, Firas Zahr, et al.
JACC. Cardiovascular Interventions|September 10, 2021
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent ImplantationRoxana Mehran, Davide Cao, Dominick J Angiolillo, et al.
Lancet (London, England)|June 29, 2020
Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trialRaj R Makkar, Wen Cheng, Ron Waksman, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 26, 2014
Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgeryMichael J Reardon, David H Adams, Joseph S Coselli, et al.
The New England Journal of Medicine|November 18, 2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsLaura Mauri, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American College of Cardiology|November 19, 2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCIMarco Valgimigli, Davide Cao, Dominick J Angiolillo, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 22, 2024
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromesDavide Cao, Pascal Vranckx, Marco Valgimigli, et al.
Journal of the American College of Cardiology|February 1, 2023
Transcatheter Edge-to-Edge Repair in Patients With Anatomically Complex Degenerative Mitral RegurgitationJörg Hausleiter, D Scott Lim, Linda D Gillam, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 16, 2025
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programmeAngelo Oliva, Dominick J Angiolillo, Marco Valgimigli, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|April 1, 2014
Transcatheter aortic-valve replacement with a self-expanding prosthesisDavid H Adams, Jeffrey J Popma, Michael J Reardon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 18, 2021
Early outcomes from the CLASP IID trial roll-in cohort for prohibitive risk patients with degenerative mitral regurgitationD Scott Lim, Robert L Smith, Firas Zahr, et al.
JACC. Cardiovascular Interventions|September 10, 2021
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent ImplantationRoxana Mehran, Davide Cao, Dominick J Angiolillo, et al.
Lancet (London, England)|June 29, 2020
Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trialRaj R Makkar, Wen Cheng, Ron Waksman, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 26, 2014
Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgeryMichael J Reardon, David H Adams, Joseph S Coselli, et al.
The New England Journal of Medicine|November 18, 2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsLaura Mauri, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American College of Cardiology|November 19, 2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCIMarco Valgimigli, Davide Cao, Dominick J Angiolillo, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 22, 2024
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromesDavide Cao, Pascal Vranckx, Marco Valgimigli, et al.
Journal of the American College of Cardiology|February 1, 2023
Transcatheter Edge-to-Edge Repair in Patients With Anatomically Complex Degenerative Mitral RegurgitationJörg Hausleiter, D Scott Lim, Linda D Gillam, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 16, 2025
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programmeAngelo Oliva, Dominick J Angiolillo, Marco Valgimigli, et al.
Pageof 9